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Background
Tumour cells relies mostly on glycolysis to meet their
energetic demands thus leading to an overload of lactic
acid, which must be exported to the extracellular milieu,
through the monocarboxylate transporters (MCTs). Due
to their upregulation in cancer, MCTs are currently
seen as promising therapeutic targets in cancer. Color-
ectal carcinoma (CRC) is the second most common type
of cancer worldwide, being mainly a disease of industria-
lized countries. Among the chemotherapeutic agents
used in the treatment of CRC, 5-fluorouracil (5-FU) is
one of the most efficient, although resistance to 5-FU
treatment has been reported. We aimed at understand-
ing the role of MCTs in the glycolytic metabolism of
CRC and exploring these transporters as putative thera-
peutic targets.
Patients and methods
We performed a detailed characterization of MCT
expression in a CRC clinical series and correlated the
expression with key metabolic proteins. We also studied
the effects of MCT activity inhibition in normal and
CRC derived cell lines and evaluated the effect of MCT
inhibitors in combination with 5-FU.
Results
Our results showed that MCT1 and MCT4, their putative
chaperones (CD147 and CD44) and the glucose transpor-
ter GLUT1 are overexpressed in CRC samples. Further-
more, we observed that MCT expression is associated
with the remaining proteins. In in vitro assays, we
demonstrated that MCT inhibition disrupted tumour cell
aggressiveness and potentiated the cytotoxic effect of
5-FU.
Conclusions
Our results provide novel evidence for the pivotal role
of MCTs in CRC maintenance, supporting the exploita-
tion of MCTs as therapeutic targets in CRC.
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